Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 26777
1. European Patent number 0451216. Queen, Humanized Immunoglobulin and Their Production and Use.
2. U.S. patent divisional applications numbers 08/487,200, 08/477,728,08/474,040 of issued U.S. patent number 5,530,101, Queen, Improved Humanized Immunoglobulin.
3. Japan patent application number 4-503758, Queen, et al. Improved Humanized Immunoglobulin.
4. U.S. Patent No. 5,693,761, Queen, et al. Polynucleotides Encoding Improved Humanized Immunoglobulin, issued December 2, 1997.
5. U.S. Patent No. 5,693,762, Queen, et. a1. Humanized Immunoglobulin, issued December 2, 1997.
IPSCIO Record ID: 26999
See article in other licensing detail that describes the current on-going legal debate surrounding this license.
IPSCIO Record ID: 273472
Anti-IgE Product shall mean any human pharmaceutical formulation containing or comprising an Anti-IgE Antibody alone or in combination with other active or inactive ingredients, components or materials in the same formulation as the Anti-IgE Antibody.
Anti-IgE Products include, without limitation, Xolair, and Hu-901.
Anti-IgE Antibodies are to be Hu-901and E-25 but not limited to.
Hu-901 shall mean the Anti-IgE Antibody and/or Anti-IgE Product which is known by the Parties as of the Effective Date as â€œHu-901â€, â€œTNX-901,â€
Xolair shall mean any product containing the Anti-IgE Antibody â€œE-25â€ or â€œomalizumabâ€ (and modifications thereto resulting solely from changes in the Manufacturing process thereof), including without limitation, the Anti-IgE Product Approved by the FDA as of June 20, 2003.
E-25â€ shall mean the Anti-IgE Antibody and/or Anti-IgE Product.
Antibody shall mean any immunoglobulin protein (excluding any immunoadhesins), and any fragment, less than full-length antibody form (such as Fv, Fab, and F(abâ€™)2), single-chain antibody, or antibody conjugate bound to a toxin, label or other moiety which, in each case, includes one or more CDRs and is capable of immunospecific binding to an antigen, regardless of the method or means by which such immunoglobulin protein, fragment, less than full-length antibody form, single-chain antibody or antibody conjugate is produced.
IPSCIO Record ID: 290397
For the License Grant, Licensor grants a nonexclusive, non-sublicensable, sublicense under the exclusive rights granted to Licensor herein to research, develop, make and use (but not to, have made, sell, or offer for sale) Licensed Biologic Products for Licensee internal research only.
Licenses to Licensee Under the Queen Patents
Licensor grants through the fifth anniversary of the Effective Date the right, upon written notice to Licensor, to receive licenses under the Licensor Antibody Humanization Patent Rights for the Licensee Antigens. Licensee shall identify each Licensee Antigen prior to IND Filing for the associated Licensed Queen Product. Each license shall be a nonexclusive, worldwide, transferable, license under the Licensor Antibody Humanization Patent Rights to make, have made, use, import, offer for sale and sell or otherwise dispose of Licensed Queen Product pursuant to a Licensor License Agreement to be executed by the Parties after such written notice.
Licensor Antigens shall mean an antigen selected by Licensee and approved by Licensor for the grant by Licensor to Licensee of a license to its Licensor Antibody Humanization Patent Rights, up to a limit of three antigens. Licensee shall identify each such Licensee Antigen after the Effective Date, but no later than the IND filing date for each associated Licensed Queen Product.
Licensed Queen Products shall mean any Antibody that binds to an Licensee Antigen whose development, manufacture, import, export, use, offer for sale or sale would infringe a Valid Queen Claim absent a license to one or more of the Queen Patents.
Diagnostic Field shall mean any use for the diagnosis, prognosis, or monitoring of a human disease or disorder.
IPSCIO Record ID: 116563
Each license shall be a nonexclusive, worldwide license under the Licensors Patent Rights to make, have made, use, import, market, promote, offer for sale and sell or otherwise dispose of Antibodies pursuant to a Licensors License Agreements. The rights of Licensee shall include the right to grant sublicenses for Antibodies in accordance with the terms of the applicable License Agreement.
The Antigens are target molecules to which an Antibody specifically binds and includes all epitopes on that target molecule.
The licensed product means an Antibody with respect to which Licensee has either significant marketing rights or has done significant development, including without limitation created, humanized or conducted preclinical or clinical development, the manufacture, import, use, offer to sell or sale of which would infringe, if not licensed under this Agreement, also known as a Valid Claim.